| Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma MS Davids, AW Roberts, JF Seymour, JM Pagel, BS Kahl, WG Wierda, ... Journal of Clinical Oncology 35 (8), 826-833, 2017 | 792 | 2017 |
| Efficacy of venetoclax as targeted therapy for relapsed/refractory t (11; 14) multiple myeloma S Kumar, JL Kaufman, C Gasparetto, J Mikhael, R Vij, B Pegourie, ... Blood, The Journal of the American Society of Hematology 130 (22), 2401-2409, 2017 | 548 | 2017 |
| Serine proteases and their homologs in the Drosophila melanogaster genome: an initial analysis of sequence conservation and phylogenetic relationships J Ross, H Jiang, MR Kanost, Y Wang Gene 304, 117-131, 2003 | 366 | 2003 |
| Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind … SK Kumar, SJ Harrison, M Cavo, J de la Rubia, R Popat, C Gasparetto, ... The Lancet Oncology 21 (12), 1630-1642, 2020 | 337 | 2020 |
| Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM P Moreau, A Chanan-Khan, AW Roberts, AB Agarwal, T Facon, S Kumar, ... Blood, The Journal of the American Society of Hematology 130 (22), 2392-2400, 2017 | 296 | 2017 |
| Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma VA Pullarkat, NJ Lacayo, E Jabbour, JE Rubnitz, A Bajel, TW Laetsch, ... Cancer discovery 11 (6), 1440-1453, 2021 | 216 | 2021 |
| STAT3: an important regulator of multiple cytokine functions SM Stepkowski, W Chen, JA Ross, ZS Nagy, RA Kirken Transplantation 85 (10), 1372-1377, 2008 | 116 | 2008 |
| The PHB1/2 phosphocomplex is required for mitochondrial homeostasis and survival of human T cells JA Ross, ZS Nagy, RA Kirken Journal of biological chemistry 283 (8), 4699-4713, 2008 | 115 | 2008 |
| Searching in mother nature for anti-cancer activity: anti-proliferative and pro-apoptotic effect elicited by green barley on leukemia/lymphoma cells E Robles-Escajeda, D Lerma, AM Nyakeriga, JA Ross, RA Kirken, ... PloS one 8 (9), e73508, 2013 | 106 | 2013 |
| Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma LJ Costa, FE Davies, GP Monohan, T Kovacsovics, N Burwick, ... Blood Advances 5 (19), 3748-3759, 2021 | 98 | 2021 |
| Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t (11; 14) multiple myeloma JL Kaufman, C Gasparetto, FH Schjesvold, P Moreau, C Touzeau, ... American journal of hematology 96 (4), 418-427, 2021 | 97 | 2021 |
| A phase I first-in-human study of ABBV-383, a B-cell maturation antigen× CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma A D'souza, N Shah, C Rodriguez, PM Voorhees, K Weisel, OF Bueno, ... Journal of Clinical Oncology 40 (31), 3576-3586, 2022 | 86 | 2022 |
| Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study S de Vos, LJ Swinnen, D Wang, E Reid, N Fowler, J Cordero, M Dunbar, ... Annals of Oncology 29 (9), 1932-1938, 2018 | 74 | 2018 |
| Regulation of T cell homeostasis by JAKs and STATs JA Ross, ZS Nagy, H Cheng, SM Stepkowski, RA Kirken Archivum immunologiae et therapiae experimentalis 55, 231-245, 2007 | 68 | 2007 |
| Forskolin inducible cAMP pathway ZS Nagy, RA Kirken, G Rodriguez, JA Ross | 65* | 2013 |
| Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies AE Place, K Goldsmith, JP Bourquin, ML Loh, L Gore, DA Morgenstern, ... Future Oncology 14 (21), 2115-2129, 2018 | 63 | 2018 |
| Phosphoproteomic analysis of the human pathogen Trypanosoma cruzi at the epimastigote stage ES Nakayasu, MR Gaynor, TJP Sobreira, JA Ross, IC Almeida Proteomics 9 (13), 3489-3506, 2009 | 59 | 2009 |
| Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t (11; 14) NJ Bahlis, R Baz, SJ Harrison, H Quach, SJ Ho, AJ Vangsted, T Plesner, ... Journal of Clinical Oncology 39 (32), 3602-3612, 2021 | 58 | 2021 |
| Signal transducer and activator of transcription 5b (Stat5b) serine 193 is a novel cytokine-induced phospho-regulatory site that is constitutively activated in primary … A Mitra, JA Ross, G Rodriguez, ZS Nagy, HL Wilson, RA Kirken Journal of Biological Chemistry 287 (20), 16596-16608, 2012 | 55 | 2012 |
| Protein phosphatase 2A regulates interleukin-2 receptor complex formation and JAK3/STAT5 activation JA Ross, H Cheng, ZS Nagy, JA Frost, RA Kirken Journal of Biological Chemistry 285 (6), 3582-3591, 2010 | 52 | 2010 |